cyrilzakka/clinical-trials huggingface dataset:
Nutritional Adaptations to Physical or Sedentary Activities in Youth

Sedentary behaviors have been shown to increase food consumption among youth and adults. The recent active video games devices have been suggested to compensate for the increased energy intake they induce by the increased energy expenditure they generate. To date no study has been conducted to question whether or not such modern sedentary activities induce energy consumption modification in youth. The aim of this work is to compare the impact of a passive video games vs. active video games vs. physical exercise in terms of subsequent energy intake and appetite feelings in normal weight and obese youth.

After a medical inclusion, the adolescents will have to realise a DXA to assess their body composition and a submaximal exercise to evaluate their aerobic capacities.

They will have then to enter the laboratory on three different occasions in a randomized order from 8am to 730pm: At 8am they will receive a calibrated breakfast. then, at 1045; they will have to complete one of the experimental condition: 1) one hour of passive video game; 2) one hour of active video game; 3) a cycling exercise. at 1215 and 0630pm, they will be offered ad libitum meals. At regular intervals through the day, their appetite feelings will be assessed using Visual analogue scales.

Energy expenditure will be assessed thanks to cardiofrequencemeters during the 1h PVG and and by indirect calomitery (K4b2) during the active video game.

Ad libitum energy consumption will be assessed by investigators and recorded for each participants.

Eligibility Criteria:
Inclusion Criteria:

* male
* 12-15 years old
* BMI defining obesity (Cole et al., 2000)
* Not being under diet restriction
* Information and consent forms have to be signed by the adolescent and his legal representative
* being registered to the national social security system

Exclusion Criteria:

* Being under medication
* contraindication to exercise
* smokers
* dieting
Alzheimer's Disease Acitretin Medication

The trials investigates the changes of cerebral spinal fluid (CSF) soluble alpha-secretase cleaved APP (APPsα) levels under oral therapy with acitretin 30mg daily in patients with mild to moderate Alzheimer's disease (AD).The present study aims to demonstrate an enhancement of the α-secretase activity by acitretin as measured by increased CSF APPSα levels in human AD. Second, the safety and tolerability of acitretin in AD patients should be proven.


Eligibility Criteria:
Inclusion Criteria:

* mild to moderate AD (NINCDS-ADRDA criteria)
* Mini-Mental State Examination (MMSE): 27-14 points
* Geriatric Depression Scale ≤ 14

Exclusion Criteria:

* hereditary cognitive impairment
* known history of brain injuries
* Insufficient German language skills
* actual treatment with other potential disease modifying drugs of AD
* multimorbidity or significant organ (esp. liver or renal) dysfunction
* evidence of Non-AD neurodegenerative disorder (e.g. Parkinson)
* contraindication to acitretin such as osteoporosis, hypoalbuminaemia
Botulinum Toxin Type A and Modified Constraint-Induced Movement Therapy for Poststroke Upper Extremity Spasticity

Botulinum toxin type A (BtxA) injection and modified constraint-induced movement therapy (mCIMT) are both promising approaches to enhance recovery after stroke. However, the combined application of the two modalities has rarely been studied. The aim was to investigate whether combined BtxA and mCIMT would produce greater improvements in spasticity and upper extremity function than BtxA plus conventional rehabilitation in chronic stroke patients with upper extremity spasticity.

Botulinum toxin type A (BtxA) injection and modified constraint-induced movement therapy (mCIMT)are both promising approaches to enhance recovery after stroke. However, the combined application of the two modalities has rarely been studied. To date, only a single case report addressed this issue. Theoretically, application of a mCIMT program with intensive functional tasks practice after spasticity reduction by BtxA may improve affected upper extremity function in patients with poststroke spasticity. The aim was to investigate whether combined BtxA and mCIMT would produce greater improvements in spasticity and upper extremity function than BtxA plus conventional rehabilitation in chronic stroke patients with upper extremity spasticity.

Eligibility Criteria:
Inclusion Criteria:

* age 18 to 80 years
* at least 1 year after a unilateral stroke
* modified ashworth scale (MAS) score \> 3 in the elbow, wrist or finger flexors
* ability to actively extend \> 10 degrees at metacarpophalangeal and interphalangeal joints and 20 degrees at wrist of the affected upper limb (minimal motor criteria).

Exclusion Criteria:

* presence of fixed joint contractures
* serious balance problems
* preexisting neurological deficits, neuromuscular diseases or uncontrolled medical conditions
* significant cognitive deficits (Mini-Mental Status Examination score \< 24)
* excessive pain in the affected upper limb
* previous treatment with Botulinum toxin A, neurolytic agents or surgery for spasticity

All patients were not currently participating in any experimental studies and did not receive concomitant oral anti-spastic medication during the study period
Effectiveness of Mobility Exercises in Resistance-Trained Males With Shoulder Immobility in Different Age Groups

The shoulder is a dynamic and mobile joint between the arm and the trunk. The movement of the joint in three dimensions performs complex movements in almost every activity of daily life.

These movements performed during activities of daily living can cause musculoskeletal problems and shoulder pathologies. For this reason, the shoulder joint should be carefully evaluated, especially in athletes.

The shoulder consists of four functional joints. Glenohumeral joint (GH), acromioclavicular joint (AC), sternoclavicular joint (SC), and scapulothoracic joint (ST). The most mobile of these four joints is the glenohumeral joint, located between the scapula and the glenoid. The GH is a synovial joint that has three-dimensional motion, covers the intra-articular capsule, and wraps the biceps long head tendon to the biceps sulcus. The glenohumeral capsule, glenohumeral ligament, and coracohumeral ligament contain a capsuloligamentous complex structure. This complex structure and the rotator cuff tendons form a static and dynamic restrictive structure around the glenohumeral joint. The rotator cuff space forms a triangular tissue between the edge of the anterior supraspinatus tendon and the superior subscapularis, and the apex is located on the lateral ridge of the biceps sulcus at the edge of the humeral ligament.

After providing mobility, movement and balance will return to stability. Increasing muscle strength for joint stabilization is a physical training goal for the shoulder in athletes.

Bone mechanics, intra-articular pressure, glenohumeral labrum and capuloligamentous structures are static components.

Dynamic components are provided by muscle activity coordinated around the joint and modulated by the neuromuscular system.

The basis of static and dynamic interactions is mainly proprioceptive inputs that occur with mechanoreceptors in the muscles, joint capsule ligaments, tendons and skin, which are integrated into each other.

Joint stabilization is provided by the coactivation force of dynamic shoulder stabilizers.

The balance of such forces must be proportional. For this reason, exercises to provide joint stabilization should aim to provide equal force distribution around the joint.

Among the criteria for evaluating the athletes; proprioception and range of motion.

Body Awareness Questionnaire aims to evaluate body awareness. Posture will be evaluated with New York posture analysis.

As a result of the literature review carried out; As far as is known, there is no adequate, up-to-date and evidence-based study in the literature.

Eligibility Criteria:
Inclusion Criteria:

* Resistance-trained males over the age of 18 with shoulder immobility.

Exclusion Criteria:

* The criteria for exclusion from the study were: having orthopedic or neurological problems, and having undergone upper extremity musculoskeletal surgery.

  * Female resistance-trained,
  * Athletes under the age of 18 will not be included in the study.
Multimodal Prehabilitation in Thoracic Surgery

This trial aims to assess the impact of a multimodal prehabilitation program in high-risk patients undergoing lung resection surgery.

This trial aims to assess the cost-effectiveness of a multimodal prehabilitation program in high-risk patients undergoing lung resection surgery. Secondary objectives are to evaluate the impact of the intervention on: i) Healthcare resuorces use; ii) clinical outcomes; and, iii) patient's and professionals experience with the program.

The program includes X main interventions: i) A motivational interview; ii) A high-intensity exercise training program; iii) A plan for physical activity incentivation; iv) A nutritional optimization program; v) A psicologichal support program; and, vi) A smoking cessation program.

Eligibility Criteria:
Inclusion Criteria:

1. Forced espiratory volume in the first second (FEV1) and/or estimated postoperative lung diffusion capacity for carbon monoxide \< 60%; and/or,
2. American Society of Anesthesiologist (ASA) index 3-4; and/or,
3. Peak oxygen uptake among 10-20 mL/kg/min.

Exclusion Criteria:

1. Non-elective surgery;
2. Metastasic disease;
3. Unestable cardiac or respiratory condition; 4) Cognitive or locomotor limitations precluding the adherence to the program.
The Impact of a Modified Probe Tip Design on Patient Perception of Discomfort on Probing and Clinical Parameters Using the Florida Probe® System

Patient perception of pain on periodontal probing using a controlled-force, electronic probe was not significantly affected by the use of a modified (ball-end) probe tip design except for in the maxilla, where a standard straight probe tip appeared to be more comfortable for patients.

Recordings of periodontal probing pocket depth (PPD) and probing attachment level (PAL) are utilized in diagnosis of periodontal disease and monitoring of disease progression. Manual probing presents reproducibility and accuracy issues based on features such as probe tip design, force applied by the operator and inflammatory status of the periodontal tissues. Evidence from the literature suggests that some patients may determine periodontal probing to be a painful experience.

The aims of this study are to evaluate the suitability of a new titanium probe tip for periodontal probing, and to evaluate pain on periodontal probing, in comparison to the existing probe tip used in the Florida Probe® system.

The study will be a randomized, blinded, split-mouth controlled trial. Twenty (20) consecutive patients meeting the inclusion criteria will be selected to undergo full-mouth periodontal probing. One half (upper or lower jaw) of the mouth will be probed using the current, standard probe tip; the opposing jaw will be probed using the new trial tip. At a second visit (within 2 weeks), prior to treatment, the mouth will be probed once again, alternating the jaws from the first visit.

On each occasion, patients will report on pain on probing utilizing two ungraded 100mm horizontal visual analogue scales (VAS) representing upper and lower jaws of the mouth.

Periodontal probing depth measurements will be compared to assess the reproducibility of the two probe tips.

Mean VAS values and standard deviations will be calculated for the test and control groups. Data analysis will be conducted using a non-parametric statistical model (Mann-Whitney U Test).

Inclusion criteria:

* Adult patients: age greater than 18 years.
* At least 4 tooth sites with periodontal probing pocket depth (PPD) greater or equal to 4mm.

Exclusion criteria:

- Patients using ongoing daily chronic analgesic medications (NSAIDs etc) for over 3 months.

Eligibility Criteria:
Inclusion criteria:

* Age greater than 18 years.
* Must have 4 tooth sites with periodontal probing pocket depth (PPD) greater or equal to 4mm.

Exclusion criteria:

- Daily use of analgesic medications (NSAIDs etc) for over 3 months.
Dead Space in Mechanical Ventilation With Constant Expiratory Flow

Conventional continuous mandatory mechanical ventilation relies on the passive recoil of the chest wall for expiration. This results in an exponentially decreasing expiratory flow.

Flow controlled ventilation (FCV), a new ventilation mode with constant, continuous, controlled expiratory flow, has recently become clinically available and is increasingly being adopted for complex mechanical ventilation during surgery.

In both clinical and pre-clinical settings, an improvement in ventilation (CO2 clearance) has been observed during FCV compared to conventional ventilation. Recently, Schranc et al. compared flow-controlled ventilation with pressure-regulated volume control in both double lung ventilation and one-lung ventilation in pigs. They report differences in dead space ventilation that may explain the improved CO2 clearance, although their study was not designed to compare dead space ventilation within the group of double lung ventilation.

Dead space ventilation, or "wasted ventilation", is the ventilation of hypoperfused lung zones, and is clinically relevant, as it is a strong predictor of mortality in patients with the acute respiratory distress syndrome (ARDS) and is correlated with higher airway driving pressures which are thought to be injurious to the lung (lung stress).

This trial aims to study the difference in dead space ventilation between conventional mechanical ventilation in volume-controlled mode and flow controlled-ventilation.


Eligibility Criteria:
Inclusion Criteria:

* Adults \[18-70\] yrs
* General anaesthesia for elective surgery
* Arterial line, central venous line and endotracheal tube as part of standard of care
* Expected duration of controlled mechanical ventilation ≥ 60 minutes
* Supine position (0±10°)

Exclusion Criteria:

* One lung ventilation
* Known pregnancy
* Increased intra-abdominal pressure (pneumoperitoneum or obesity (BMI \> 30kg/m2))
* COPD GOLD IV or home oxygen dependence
* Cardiac pacemaker, implantable cardioverter-defibrillator (ICD) or thoracic neurostimulator
* Skin lesions (e.g. injury, inflammation) at the level where the Electrical Impedance Tomography (EIT) band is to be applied
* Clinical signs of raised intracranial pressure
* Potential interference with the surgery due to the setup of the study instruments.
* Patient refusal to participate
Study of Rivaroxaban for CeREbral Venous Thrombosis

SECRET examines the safety of rivaroxaban versus standard-of-care for treatment of symptomatic cerebral venous thrombosis, initiated within 14 days of diagnosis.

SECRET is an open-label, randomized, controlled, phase II study that will assess the safety of rivaroxaban, a non-vitamin K antagonist oral anticoagulant (NOAC), compared with standard-of-care (unfractionated or low-molecular weight heparin with transition to warfarin \[INR 2.0-3.0\], or continued low molecular-weight heparin) for cerebral venous thrombosis. Recruitment will occur at 17 high-volume stroke research centres across Canada over 3 years. During the pilot phase, 50 adult patients within 14 days of symptomatic cerebral venous thrombosis diagnosis will be randomized to receive rivaroxaban 20 mg daily versus standard of care (warfarin or low-molecular weight heparin). Patients will be followed for 1 year. The feasibility of recruitment will be tested during the pilot phase and outcomes refined for a future Phase III trial.

Eligibility Criteria:
Inclusion criteria:

1. Patients aged 18 and above
2. New diagnosis of symptomatic cerebral venous thrombosis as confirmed on CT venogram or MR venogram
3. Ability to randomize within 14 days of neuroimaging-confirmed diagnosis
4. The treating clinician is of the opinion that the patient is appropriate for oral anticoagulation as per standard of care
5. Patient or legally authorized representative is able to give written informed consent

Exclusion criteria:

1. Patient has known antiphospholipid antibody syndrome (APLS; lupus anticoagulant, anti-beta 2-glycoprotein I antibodies, and anticardiolipin antibody) by Sapporo-Sydney criteria with a previous history of venous or arterial thrombosis
2. Patient is anticipated to require invasive procedure (e.g. lumbar puncture, thrombectomy, hemicraniectomy) prior to initiation of oral anticoagulation\*\*
3. Patient is unable to swallow due to depressed level of consciousness†
4. Impaired renal function (i.e., CrCl \< 30 mL/min using Cockroft-Gault equation)
5. Pregnancy; if a woman is of childbearing potential a urine or serum beta human chorionic gonadotropin (β-hCG) test is positive
6. Breastfeeding at the time of randomization
7. Bleeding diathesis or other contraindication to anticoagulation
8. Any concurrent medical condition requiring mandatory antiplatelet or anticoagulant use
9. Concomitant use of strong CYP3A4 inducers (e.g., ongoing use of dilantin, carbamazepine, HIV protease inhibitors) or CYP3A4 inhibitors (e.g., diltiazem, ketoconazole)
10. Patient has a severe or fatal comorbid illness that will prevent improvement, or cannot complete follow-up due to the same, or cannot complete follow-up due to co-morbid non-fatal illness, non-residence in the city, or for any other known reason for which follow-up would be impossible.
Korea Hip Replacement Surgery Registry

This cohort study obtained data from the Korean National Health Insurance Service (K-NHIS) database. For the hip replacement registry, we included all adult patients older than 19 who received total or hemiarthroplasty surgery between January 1, 2003, and December 31, 2019. Using this registry, we compared efficacy and safety by type of head or liner.

This cohort study obtained data from the Korean National Health Insurance Service (K-NHIS) database. For the hip replacement registry, we included all adult patients older than 19 who received total or hemiarthroplasty surgery between January 1, 2003, and December 31, 2019. Using this registry, we compared efficacy and safety by type of head or liner. The safety issues included the incidence of cancer, orthoperiodic outcome (dislocation, mechanical Cx, periprosthetic join infection, periprosthetic fracture), revision, embolism or thrombosis, cardiac outcome, and death

Eligibility Criteria:
Inclusion Criteria:

* Patient aged 19 or older who received hip replacement surgery

Exclusion Criteria:

* Insufficient information
* history of any revision
Rehabilitation Nursing Program in Otolaryngology

The European Commission's current political guidelines demonstrate into a joint plan aimed at improving and controlling cancer disease. Head and neck cancer (HNC) are the sixth most common cancer worldwide. The surgery is one of the most effective treatments, however it significantly compromises the self-care and functional capacity of the patients, so the intervention the Rehabilitation Nurse (RN) is essential.

Objective: Compare the degree of dependence in discharge from patients undergoing HNC surgery with RN intervention versus general nursing care (not RN intervention). The specific objective is to analyze the role of confounders in the effect of the RN intervention on the patient dependence.

Seventy-nine patients with RN intervention who undergoing a different type of surgery (1-Neck dissection, 2-Total laryngectomy with neck dissection, 3-Pelviglossomandibulectomy with neck dissection and tracheotomy, 4-Pelviglossomandibulectomy with neck dissection, pectorals major flap and tracheotomy) and all patients who undergoing the same type of surgery without RN intervention (n=72).

Seventy-nine patients with RN intervention who undergoing a different type of surgery (1-Neck dissection, 2-Total laryngectomy with neck dissection, 3-Pelviglossomandibulectomy with neck dissection and tracheotomy, 4-Pelviglossomandibulectomy with neck dissection, pectorals major flap and tracheotomy) and all patients who undergoing the same type of surgery without RN intervention (n=72). Differences between groups were calculated using non-parametric tests Chi-square for categorical variables and Mann-Whitney U for numeric variable. After correlation tests between variables, statistical analysis was carried out through Poisson regression to a significance level of 5%.

Eligibility Criteria:
Inclusion Criteria:

* Undergoing a different type of surgery: 1-Neck dissection, 2-Total laryngectomy with neck dissection, 3-Pelviglossomandibulectomy with neck dissection and tracheotomy, 4-Pelviglossomandibulectomy with neck dissection, pectorals major flap and tracheotomy.

Exclusion Criteria:

* Participants will be excluded if not be possible access of the clinical information.
Effect of Adjuvant Chemotherapy Cycles on Patients With Node-negative Gastric Cancer Following Neoadjuvant Chemotherapy

To explore the effect of adjuvant chemotherapy cycles on the prognosis of this specific patient with lymph node-negative gastric cancer following neoadjuvant chemotherapy.

We analyzed clinicopathological data from patients with lymph node-negative gastric cancer who underwent neoadjuvant chemotherapy at four institutions between 2010 and 2020. The 3-year OS was assessed using landmark analysis. Independent risk factors associated with 3-year OS were identified using a Cox proportional hazards regression model.

Eligibility Criteria:
Inclusion Criteria:

* (1) preoperative neoadjuvant chemotherapy; (2) primary gastric adenocarcinoma, diagnosed by gastroscopic pathology findings before neoadjuvant chemotherapy in complete pathological remission (pCR) cases or via postoperative pathology findings in all other instances; (3) absence of distant metastases in the liver, lungs, or abdominal cavity, as confirmed by preoperative chest radiography or chest computed tomography (CT), abdominal ultrasonography, abdominal CT, and other imaging; (4) radical gastric cancer surgery (R0) and D2 lymph node dissection; and (5) postoperative pathologic verification of no lymph node metastasis (i.e., lymph node-negative).

Exclusion Criteria:

* (1) preoperative radiotherapy or radiochemotherapy, (2) discovery of distant metastases preoperatively or intraoperatively, (3) coexistence of other malignant tumors, (4) residual gastric cancer, and (5) perioperative patient mortality.